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Summary
Background After publishing promising results for
the treatment of patients with human papilloma
virus (HPV) positive oropharyngeal cancer with ra-
diochemotherapy regarding 2-year survival, we present
an update of the disease-specific and disease-free sur-
vival after 5 years.
Patients and methods A total of 29 patients of which
18 were HPV negative and 11 HPV positive with squa-
mous cell carcinoma of the oropharynx received ra-
diation therapy with or without chemotherapy (cis-
platin) or immunotherapy (cetuximab) between 2007
and 2009. At time of the present analysis, six patients
are still alive including four with HPV positive and two
with HPV negative oropharyngeal carcinoma, while 15
out of 16 patients with HPV negative tumors died and
1 died of another cause with evidence of disease.
Results Since the 2-year disease-specific survival of
patients with HPV positive cancer of the oropharynx
was published with 100% versus 30.4% in HPV nega-
tive tumors, we now present the 5-year disease-spe-
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cific survival after treatment, which was 85.7% in HPV
positive versus 11.1% in HPV negative patients.
Conclusion We present the results of patients receiv-
ing radiochemo(immuno)therapy for oropharyngeal
cancer regarding the HPV status, which is still promis-
ing.
Keywords Oropharyngeal cancer · Human papilloma
virus · Radiochemotherapy · Update
Introduction
The development of squamous cell carcinomas of the
head and neck (SCCHN) is mainly caused by com-
monly known risk factors including alcohol and to-
bacco abuse. In the last 15 years human papilloma
virus (HPV) infections became recognized as a ma-
jor risk factor for oropharyngeal cancer [1–3]. The
prevalence of SCCHN with over 500,000 new cases per
year worldwide is high [4], whereas the incidence of
pharyngeal carcinoma is approximately 136,000 and
oropharyngeal cancer is on the rise [5]. In Austria, the
incidence of head and neck cancer increased from 567
newly diagnosed carcinomas in 1983 to 1085 head and
neck cancer patients in 2012, while 418 patients with
head and neck carcinomas died related to the disease
in 1983 and 493 patients in 2014 [6]. A marked in-
crease in the incidence of oropharyngeal cancer has
been observed in the last decade in Austria [6] and
other countries [7, 8]. At the same time HPV positivity
increased 2.9 fold in the USA [7] and in Europe [8]. The
incidence of oropharyngeal carcinoma predominantly
increased in younger patients and in this patient col-
lective especially in male patients, probably because
of the higher prevalence of HPV in cervical than in pe-
nile tissue [9, 10], transmitted by orally performed sex-
ual contact [10]. Recently, HPV detection in biopsies
of head and neck cancer taken during routinely per-
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formed panendoscopy became routine practice. On
average, 23.5% of oral cavity cancers, 24% laryngeal,
36.5% oropharyngeal and approximately 50% of tonsil
carcinomas are HPV positive [1, 9] and we and others
experienced that patients with HPV positive oropha-
ryngeal cancer show a better outcome concerning re-
sponse to treatment, overall and disease-free survival.
At present, no recommendations for modification
of therapy exist, but there are de-escalation studies,
e. g. replacing cisplatin by cetuximab in HPV positive
patients [11, 12]. Another study consists of an induc-
tion chemotherapy with docetaxel, cisplatin and 5-FU.
In the case of a response, a reduced dose of radio-
therapy plus/minus chemotherapy is administered, in
the case of stable or progressive disease standard ra-
diochemotherapy is performed [13, 14].
In the present manuscript we present the current
results of disease-specific overall survival and dis-
ease-free survival of HPV positive versus negative
patients with cancer of the oropharynx treated with
radiochemotherapy or radioimmunotherapy in the
years 2007–2009.
Patients and methods
The study presented in 2010 was performed as a retro-
spective analysis [9]. All patients with oropharyngeal
cancer who refused surgical treatment or where the
tumors were locally unresectable (T4b, non-resectable
according to the UICC/AJCC classification [9]) were
included in the study. For this analysis, 88 patients
with SCCHN were screened for HPV during routinely
performed panendoscopy between 2007 and 2009.
A HPV multiplex PCR (polymerase chain reaction)
and an anti-HPV in situ hybridization as well as
a routinely accomplished histological examination
were carried out earlier [9]. Of these 88 patients,
45 had their tumor localization in the oropharynx,
of these 30 underwent conservative treatment com-
prising radiotherapy, radiochemotherapy or radioim-
munotherapy. This patient collective consisted of
18 HPV negative and 12 HPV positive patients. One
patient was excluded from the study due to a severe
HIV infection. The detection of HPV by PCR and in
situ hybridization was previously published elsewhere
[9].
Radiotherapy, chemotherapy and immunotherapy
The regimen was published previously and therapy
was decided in an interdisciplinary tumor board with
respect to the patients request, performance sta-
tus and comorbidities. The radiation therapy was
administered as a standard fractionation at 2Gy/
fraction/day for 5 days per week to 70Gy/35 frac-
tions/7 weeks or with accelerated fractionation with
concomitant boost at 1.8Gy/fraction/day, 5 days/
week and 1.5Gy/fraction/day to a boost field as a sec-
ond daily treatment for the last 12 therapy days to
72Gy/42 fractions/6 weeks [9].
In the case of radiochemotherapy, patients received
cisplatin in a dosage of 100mg/m2 every 3 weeks for
the duration of radiotherapy to a cumulative dose
of 300mg/m2. Patients who were not eligible for
chemotherapy (reduced performance status, elderly
patients >70 years, impaired renal function) received
immunotherapy consisting of cetuximab 400mg/m2
initial dose 1 week prior to irradiation and a weekly
dose of 250mg/m2 for 7 weeks. In three cases, pa-
tients received radiotherapy alone because of reduced
performance status, age and impaired renal function.
One patient was not treated at all for cancer as treat-
ment was refused and the patient died 3 months after
the initial diagnosis [9].
Statistical analysis
Statistical evaluation was performed as previously de-
scribed [9] but for convenience, the description will be
reprinted. Kaplan-Meier curves represent the survival
data and differences between the curves are tested
with log-rank test. All deaths, independent of their
cause, were considered as events for overall survival.
The disease-specific survival describes only deaths
concerning the underlying disease and observations
with deaths unrelated to disease were censored at the
time of death. For disease-free survival all recurrences
of the carcinoma were considered as events [9]. The
disease-specific overall survival delineates the main
outcome parameter, as second outcome parameter
we considered disease-free overall survival. All p-
values are two-sided and p ≤ 0.05 was considered sig-
nificant. All calculations were performed with SPSS
(PASW Statistics, New York, NY. Version 21.0.0.0).
Results
In this study 30 patients with oropharyngeal cancer
including carcinomas of the tonsils and base of the
tongue were treated with radiation, radiochemother-
apy or radioimmunotherapy in the years 2007–2009
and were retrospectively evaluated. One patient pre-
senting with a T4 HPV positive carcinoma of the ton-
sils was excluded from evaluation because of a se-
vere HIV infection and subsequent complete change
of the therapeutic regimen. The median age at time
of therapy was 62 years (range 46–89 years) [9]. The
patient collective included 19 male and 10 female pa-
tients, of these 6 patients are still alive and 23 have
died. Of the patients who died 7 were HPV positive
and 16 HPV negative [9]. Among the HPV positive pa-
tients, one patient died due to carcinoma, while six
died of other causes including pneumonia, myocar-
dial infarction, dilated cardiomyopathy and apoplec-
tic stroke (Table 1). Of the patients with HPV negative
carcinoma of the oropharynx, 15 died of disease and 1
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Table 1. Causesof deaths inHPVpositive versusnegative
patients
HPV+ HPV–




Myocardial infarction 2 –
General condition 1 –
Pneumonia 1 –
Cardiomyopathy 1 –
Colon perforation – 1
Tumor-related death 1 15
Alive and well 4 2
died because of a colon perforation while presenting
evident oropharyngeal carcinoma formations.
All patients received radiation in combination with
immunotherapy (cetuximab), chemotherapy (cis-
platin) or radiation alone [9]. Regarding tumor stage
of patients, 6 patients presented with T2 stage, 2 with
T3 and 21 with T4, while HPV positive patients collec-
tive comprised 6 with T2, 1 with T3 and 4 with T4 and
HPV negative included 1 with T3 and 17 with T4 tu-
mors [9]. After a period of 5 years the overall survival
of all patients was not significantly enhanced in the
HPV positive group (p = 0.190) due to a high rate of
non-disease-related deaths (n = 6) (Fig. 1). After cen-
soring the patients who died of other causes [9], the
disease-specific overall survival was calculated. The
disease-specific overall survival of patients with HPV
positive oropharyngeal carcinoma was significantly
better than in patients with HPV negative tumor (P =
0.002) (Fig. 2).
The time to first event, recurrence of death of any
cause was significantly improved in patients with HPV
positive oropharyngeal cancer (p = 0.042). After cen-
soring non disease-related deaths of patients, the dis-
ease-free survival was highly significant (p < 0.001)
(Fig. 3).
Considering only patients with T4 tumors, they are
subdivided into 4 patients with and 17 without HPV
positivity. Significant differences could be observed
for both disease-specific overall survival of T4 tumors
(p = 0.042) as well as disease-free survival (p = 0.016)
(Fig. 4).
The 5-year disease-specific overall survival was
85.7% in patients with HPV positive versus 11.1% in
HPV negative tumors.
Discussion
We intended to perform an update of the promising
results from 2010, 5 years after therapy of patients for
HPV positive and negative oropharyngeal carcinomas.
In our manuscript presented in 2010 [9] we could de-
scribe a 1-year disease-specific survival of HPV pos-
itive patients comprising 100% versus HPV negative
patients with 72.9%, whereas the 2-year overall sur-
vival was 100% compared to 30.4%. Both results were
highly significant, at the time presenting a p-value of
p = 0.015.
The present evaluation was based on the same pa-
tient collective and a re-evaluation was performed 5
years after patients started radiotherapy with or with-
out chemotherapy or immunotherapy for oropharyn-
geal cancer. All patients were tested for HPV. Only
the 29 patients evaluated in the first publication were
updated at the present study, which surely limits the
conclusion of our analysis as we present a small group
of patients.
Of the patients evaluated, six patients are still alive,
two of them are HPV negative and four HPV positive.
Of the patients 23 have died with 7 patients being
HPV positive and 16 HPV negative. The patients with
HPV positive tumor died predominantly (6 out of 7) of
other causes including apoplectic stroke, myocardial
infarction, pneumonia and reduced performance sta-
tus in a 87-year-old woman as mentioned before and
listed in Table 1. The deaths were not documented as
therapy-related deaths and none of these patients had
evident disease. Only one patient with an HPV posi-
tive oropharyngeal carcinoma experienced a regional
recurrence 10 months after therapy and died because
of recurrence one month later. On the other hand, 15
of 16 patients with HPV negative tumor died because
of a progression of their cancer, including one patient
who died of a colon ulceration but with an evident
oropharyngeal local recurrence. Of the patients with
HPV negative tumor 9 showed progression of the dis-
ease even during therapy, 1 patient had a recurrence
after 3 months, 4 after 9 months, 1 after 11 months
and 3 patients had late recurrences after 21, 37 and
67 months, respectively. As the mean age was equiv-
alent in both groups, the high rate of non-disease-
related deaths cannot be ascribed to a higher age or
more comorbidities in one group.
Overall and disease-free survival were significantly
better even matching T4 HPV positive and negative
patients with the limitation that merely four patients
with HPV positive cancer were included to the analy-
sis. These four patients had a T4a tumor with (N2b-
c) and without (N0) lymph node metastases. In a re-
cently implemented new staging system for HPV pos-
itive oropharyngeal cancer patients, they fulfil criteria
for new stage III, which is defined by T4a-b N0-3 [15].
Concerning the outcome, we could not find dif-
ferences in patients receiving immunotherapy versus
chemotherapy. In the HPV positive patient group,
seven patients received radioimmunotherapy, two
patients each radiotherapy alone or radiochemother-
apy. The patients presenting with HPV negative tu-
mors were treated with radioimmunotherapy in seven
cases, radiochemotherapy in nine and radiotherapy
in one case. One remaining patient refused therapy
at all. Interestingly, radiochemotherapy was admin-
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Fig. 1 Kaplan-Meier curveof theoverall survival (OS) of all pa-
tients. Subsequently, thedeathsnot related tocancerwerecen-
sored (Fig. 2).Blue line survival ofHPVpositivepatients,green
lineHPVnegative
Fig. 2 Kaplan-Meier curveof disease-specific survival (DSS).




istered more often in the HPV negative group in our
patient collective. Nevertheless, it was a retrospective
analysis and at the time of therapy no recommenda-
tions for de-escalation of therapy existed.
It has been sufficiently evidenced that patients
presenting HPV positive oropharyngeal cancer show
improved response to treatment and have a better
disease-specific as well as disease-free survival [9,
16–19]. The 5-year overall survival has been specified
with 83% in HPV positive versus 37% [20], which is
comparable to our results, predominantly concerning
the HPV positive patients. As described, the 5-year
Fig. 3 Kaplan-Meier curveof thedisease-free survival (DFS)
washighly significant inpatientswithHPVpositiveoropharyn-
geal carcinoma (p<0.001).Blue line survival ofHPVpositive
patients,green lineHPVnegative
Fig. 4 Kaplan-Meier curveof disease-free survival inpatients
presentingT4 tumor (DFS inT4). DFS is enhanced inHPVpos-
itivepatients (p=0.016). Solid line survival ofHPVpositivepa-
tients,dashed lineHPVnegative
disease-specific survival was 85.7% in HPV positive
versus 11.1% in HPV negative cancer patients in our
study. The 3-year disease-free survival is similar with
85.7% versus 22.2%, respectively. Another paper ob-
served that 90% of their patients with oropharyngeal
carcinoma were HPV positive and could show a 3-
year OS of 93% and a 5-year OS of 89% [21]. Not
only the prediction of treatment response, but also
the survival prognosis of patients with HPV positive
oropharynx carcinoma is improved, which is addi-
tionally reflected in the minimized risk of second
primaries, stated with 5.6% in HPV positive versus
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14.6% in HPV negative cancer patients [22]. Conse-
quentially, a reduction of therapeutic agents has to
be discussed and this discussion has already started
with a presentation at the American Society of Clin-
ical Oncology (ASCO) meeting in 2012. Two studies
with an overall reduced irradiation dose and replace-
ment of cisplatin by cetuximab in patients with HPV
positive oropharyngeal cancer have been presented
[14]. One study by Mehrotra et al. reduced the
dose of radiotherapy (±chemotherapy) to 66Gy in the
case of complete or partial response to an induction
chemotherapy consisting of docetaxel, cisplatin and
5-floururacil. In the group without response to treat-
ment (stable disease or progression) patients received
a standard radiochemotherapy [23]. A second study
(ECOG 1308) with induction chemotherapy (pacli-
taxel, cisplatin, cetuximab) was followed by radiation
therapy with a dose of 54Gy and cetuximab only in
the case of a complete response after three cycles of
induction chemotherapy [13]. Patients with partial re-
sponse or stable disease were conventionally treated
with standard radiotherapy and cetuximab [13].
These two studies are the first attempts to enhance
patient quality of life in a distinct group of HPV posi-
tive oropharyngeal cancer patients. As this group has
customarily less common risk factors, such as tobacco
and alcohol consumption, the prognosis is fairly good.
A reduced dose of radiotherapy and chemotherapeu-
tic agents and an extended application of the mono-
clonal Epidermal Growth Factor Receptor (EGFR) an-
tagonist cetuximab with a lower potential of adverse
events might improve the quality of life of these can-
cer patients without the risk of an early recurrence.
The ECOG 3311 is a phase II trial de-escalating ad-
juvant radiotherapy (50Gy compared to 60Gy) in the
case of intermediate risk including patients with less
than 1mm extracapsular extension and 2–4 positive
lymph node metastases or close margins [24]. So far,
there are no worldwide recommendations for reduc-
tion of therapy agents and we need to anticipate the
results of the de-escalation trials to adjust the therapy
for oropharyngeal cancer patients [26].
In addition, the potential to prevent HPV related tu-
mors, be it cervical or oropharyngeal cancer, is impli-
cated by HPV vaccination, which is included in school
vaccination programs at no charge in Austria since
February 2014. Currently, a 9-valent vaccination is
applied and achieved in 60% of girls and 40% of boys
in Austria, leading to a predicted reduction of cervical
cancer in 92%, anal cancer by 83% and should also
impact on reduction of the occurrence of oropharyn-
geal cancer [25].
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